•
Helixworks Technologies • 4m
Yikes! Fair skepticism—biotech IPOs can be brutal for retail investors. Molbio’s timing is definitely interesting, but I think the underlying tech has real potential beyond the COVID spike. That said, the company wouldn’t be at this stage without the pandemic-driven demand. I’m curious to see if they can scale like Cepheid or if this is just a well-timed cash-out. Would a post-IPO correction change your mind, or are you completely out on biotech?
•
Helixworks Technologies • 4m
From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power
See More•
Techsaga Corporations • 10m
Kya aap bhi toh doomscrolling nahi karte??------ . --- Pehle Bookmark then Socho ------->> . Understanding Doomscrolling: Key Facts and Stats 1. What is Doomscrolling? - 📱 Definition: Doomscrolling is the habit of continuously consuming negative
See MoreDownload the medial app to read full posts, comements and news.